Drug · DIN 02569876
OJEMDA
25 MG/ML AFTER RECONSTITUTION, POWDER FOR ORAL SUSPENSION SINGLE-USE
Authorized, not yet reported as sold
Authorized for sale in Canada; the company has not yet told Health Canada that it is on the market.
Status Approved since July 13, 2026.
- Drug Identification Number (DIN)
- 02569876
- Company (DIN owner)
- Ipsen Biopharmaceuticals Canada IncMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Powder For Suspension
- Route
- Oral
- Therapeutic class (ATC)
- Tovorafenib L01EC04
- Class
- Human
- Record last updated
- August 28, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| TOVORAFENIB | 25 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 13, 2026: NOC 37901New Drug Submission (NDS)
Other DINs named OJEMDA
- DIN 02569817 · Approved